IQVIA HOLDINGS Business Summary

IQVIA Holdings Inc. (IQV) is a premier global provider of advanced analytics, technology solutions, and clinical research services for the life sciences sector. As of January 1, 2026, the company operates under a streamlined reporting structure consisting of two primary segments: Commercial Solutions, which merges SaaS-based analytics with medical outsourcing, and Research & Development Solutions (R&DS), focused on clinical trial management and real-world evidence. Revenue is diversified through high-margin subscription fees for its proprietary data platforms, recurring software licensing, and project-based transaction fees for outsourced drug development. IQVIA occupies a dominant market position by leveraging the "IQVIA CORE"—a massive repository of over 1.2 billion non-identified patient records—competing directly with major industry peers such as Icon plc, Medpace Holdings, and Thermo Fisher Scientific. IQVIA was established via the 2016 merger of Quintiles, founded by Dennis Gillings, and IMS Health, led by current Chairman and CEO Ari Bousbib, a former senior executive at United Technologies. The executive team includes CFO Ronald Bruehlman, who is set to retire on February 28, 2026, to be succeeded by Michael J. Fedock, and Jim Berkshire, who serves as EVP of Global Technology and Operations. Other key leaders include Richard Staub (President, R&DS), Bhavik Patel (President, Commercial Solutions), and Chief Medical and Scientific Officer Jeffrey Spaeder, M.D. The company’s board of directors includes notable members such as Nobel laureate Dr. William G. Kaelin Jr. and John Danhakl of Leonard Green & Partners. IQVIA is backed by significant institutional investors, including The Vanguard Group, BlackRock, and State Street Corporation.